| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CDC6; CDC18L; Cell division control protein 6 homolog; CDC6-related protein; Cdc18-related protein; HsCdc18; p62(cdc6); HsCDC6 |
| Entrez GeneID | 990 |
| WB Predicted band size | Calculated MW: 63 kDa; Observed MW: 63 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | A synthetic phosphopeptide corresponding to residues surrounding Ser106 of human Cdc6 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于 **Phospho-CDC6 (Ser106) 抗体** 的参考文献示例(基于领域内常见研究主题，部分为假设性示例)：
1. **文献名称**: *"Phosphorylation of CDC6 at Serine 106 by ATM/ATR Promotes Checkpoint Activation in Response to DNA Damage"*
**作者**: Lee et al.
**摘要**: 研究揭示了 DNA 损伤后，ATM/ATR 激酶磷酸化 CDC6 的 Ser106 位点，触发细胞周期检查点停滞。该文献使用 Phospho-CDC6 (Ser106) 抗体验证磷酸化事件，并证明其调控复制起始复合物的组装。
2. **文献名称**: *"A Monoclonal Antibody Specific for Phospho-CDC6 (Ser106) Reveals Cell Cycle-Dependent Regulation in Mammalian Cells"*
**作者**: Smith et al.
**摘要**: 开发了一种高特异性单克隆抗体，用于检测哺乳动物细胞中 CDC6 的 Ser106 磷酸化。通过免疫印迹和免疫荧光实验，证明该修饰在 S 期和 DNA 损伤时显著增强。
3. **文献名称**: *"CDC6 Phosphorylation at Ser106 Mediates E2F-Dependent Transcriptional Repression in G1 Phase"*
**作者**: Garcia et al.
**摘要**: 发现 CDC6 的 Ser106 磷酸化在 G1 期通过 E2F 通路抑制复制基因转录，使用特异性抗体证明其与染色质重塑复合物的相互作用。
4. **文献名称**: *"Dysregulation of Phospho-CDC6 (Ser106) in Cancer: Implications for Genomic Instability"*
**作者**: Chen et al.
**摘要**: 分析多种癌症样本中 Phospho-CDC6 (Ser106) 的表达，发现其异常升高与基因组不稳定性及化疗耐药性相关，提示其作为潜在生物标志物的价值。
---
**注**: 以上为模拟示例，实际文献需通过 **PubMed/Google Scholar** 检索关键词(如“CDC6 Ser106 phosphorylation antibody”)获取。若需具体文献，建议补充更详细的研究背景。
The Phospho-CDC6 (Ser106) antibody is a specialized tool used to study the phosphorylation status of CDC6 (Cell Division Cycle 6), a critical regulator of DNA replication initiation during the cell cycle. CDC6 plays a key role in assembling the pre-replication complex (pre-RC) by recruiting the mini-chromosome maintenance (MCM) complex to replication origins. Its activity is tightly controlled through phosphorylation, particularly during the S phase and in response to DNA damage. Phosphorylation at Ser106. mediated by cyclin-dependent kinases (CDKs) or DNA damage-activated kinases like ATM/ATR, modulates CDC6’s stability, localization, and interaction with other replication proteins. For example, phosphorylation at this site can trigger CDC6 degradation or nuclear export, preventing re-replication and ensuring genome stability.
This antibody is widely used in research to investigate cell cycle regulation, replication stress, and checkpoint mechanisms. It helps detect phosphorylated CDC6 in techniques such as Western blotting, immunofluorescence, and immunoprecipitation. Specificity for the Ser106-phosphorylated form allows researchers to study dynamic changes in CDC6 activity during normal progression or under stress conditions (e.g., chemotherapy or radiation). Proper experimental controls, including untreated vs. phosphatase-treated samples, are essential to confirm signal specificity. Studies using this antibody have contributed to understanding how CDC6 phosphorylation impacts cancer progression, replication errors, and therapeutic responses, highlighting its relevance in both basic and translational biomedical research.
×
